VolitionRx Limited Reports Financial Results for Q3 2025
VolitionRx Limited (NYSE AMERICAN: VNRX), a pioneering epigenetics firm, has revealed its financial results and significant business developments for the third quarter of 2025. The company's leadership will host a conference call to discuss these results in detail, providing insights into the company's future direction.
Update on Collaboration Agreements
Cameron Reynolds, President and Group CEO, shared exciting news about recent commercial advancements. In its commitment to push forward with the Nu.Q® platform for human diagnostics, VolitionRx secured two prominent agreements this quarter. Notable collaborations include a Research License and Exclusive Commercial Option Rights Agreement for Antiphospholipid Syndrome (APS) with Werfen, and a Co-Marketing and Services Agreement with Hologic, both industry leaders in their respective fields.
Expanding Global Partnerships
VolitionRx is actively engaging with approximately 10 leading diagnostic firms around the globe. These discussions are at various stages of due diligence and technological transfer, including evaluating clinical samples and negotiating contract terms. The company is optimistic about securing additional human licensing agreements, with updates expected as these negotiations develop.
Clinical Evidence and Future Publications
The emerging clinical evidence supporting the application of the Nu.Q® technology in cancer and sepsis detection is promising. The management anticipates several peer-reviewed publications in the near future that will validate their groundbreaking Capture-Seq™ technology, which aims to enhance cancer detection methods significantly.
Financial Performance Overview
In the third quarter, the company reported revenue of $0.6 million, demonstrating a commendable 32% growth compared to the previous year. Operational expenses also saw a reduction, down by 10% year-on-year. Moreover, the net loss has decreased by 8%, indicating improved financial health.
Investment and Liquidity Position
VolitionRx reported net cash used in operating activities for the quarter at $3.6 million, reflecting a 33% improvement from the previous year. Following the quarter's conclusion, the company received approximately $6.1 million from a public offering, enhancing its financial resources for future initiatives.
Upcoming Conference Call Details
VolitionRx will host a conference call on November 14, 2025, at 8:30 a.m. U.S. Eastern Time. Louise Batchelor, Chief Marketing and Communications Officer, along with other key executives, will provide updates on essential events and milestones achieved during the quarter.
About VolitionRx Limited
VolitionRx is committed to transforming the landscape of disease detection through its innovative approach to epigenetics. The company is focused on developing efficient, cost-effective blood tests aiming for earlier detection of diseases, including various cancers associated with NETosis, thus improving patient outcomes. Their research and development operations are primarily based in Belgium, alongside facilities in the U.S. and London.
Future Directions and Innovations
With a dedicated innovation laboratory and a diverse portfolio of diagnostic tests, VolitionRx is advancing its mission to not only save lives but also enhance the quality of life for patients through early detection and continual monitoring of diseases. The company aims to replicate its success in the veterinary diagnostics market within the human diagnostics sector.
Frequently Asked Questions
What financial results did VolitionRx report for Q3 2025?
VolitionRx reported a revenue of $0.6 million for Q3 2025, with a 32% increase year-on-year.
What new agreements has VolitionRx established recently?
The company signed agreements with Werfen and Hologic, enhancing its commercial strategies in human diagnostics.
What are the expectations for future publications from VolitionRx?
VolitionRx anticipates several peer-reviewed publications that will include clinical evidence supporting their technology and innovations.
How does VolitionRx plan to develop further in diagnostics?
They are focused on securing additional licensing agreements and expanding partnerships within the diagnostics market.
What is the mission of VolitionRx?
VolitionRx aims to save lives through early detection of diseases and continuous monitoring, leveraging its epigenetics focus.